| Literature DB >> 24196836 |
Jason W Westerbeck1, Nagesh Pasupala, Mark Guillotte, Eva Szymanski, Brooke C Matson, Cecilia Esteban, Oliver Kerscher.
Abstract
The Slx5/Slx8 heterodimer constitutes a SUMO-targeted ubiquitin ligase (STUbL) with an important role in SUMO-targeted degradation and SUMO-dependent signaling. This STUbL relies on SUMO-interacting motifs in Slx5 to aid in substrate targeting and carboxy-terminal RING domains in both Slx5 and Slx8 for substrate ubiquitylation. In budding yeast cells, Slx5 resides in the nucleus, forms distinct foci, and can associate with double-stranded DNA breaks. However, it remains unclear how STUbLs interact with other proteins and their substrates. To examine the targeting and functions of the Slx5/Slx8 STUbL, we constructed and analyzed truncations of the Slx5 protein. Our structure-function analysis reveals a domain of Slx5 involved in nuclear localization and in the interaction with Slx5, SUMO, Slx8, and a novel interactor, the SUMO E3 ligase Siz1. We further analyzed the functional interaction of Slx5 and Siz1 in vitro and in vivo. We found that a recombinant Siz1 fragment is an in vitro ubiquitylation target of the Slx5/Slx8 STUbL. Furthermore, slx5 cells accumulate phosphorylated and sumoylated adducts of Siz1 in vivo. Specifically, we show that Siz1 can be ubiquitylated in vivo and is degraded in an Slx5-dependent manner when its nuclear egress is prevented in mitosis. In conclusion, our data provide a first look into the STUbL-mediated regulation of a SUMO E3 ligase.Entities:
Mesh:
Substances:
Year: 2013 PMID: 24196836 PMCID: PMC3873881 DOI: 10.1091/mbc.E13-05-0291
Source DB: PubMed Journal: Mol Biol Cell ISSN: 1059-1524 Impact factor: 4.138
FIGURE 1:Targeting of Slx5 depends on a nuclear-localization domain and SIMs (A) Graphic depiction of six carboxy-terminal truncations (C1–C6) of Slx5. The length of each truncation construct is indicated by the scale above, with full-length Slx5 being 620 amino acids in length. Also indicated are previously identified SIMs and the RING domain (dark gray) of the full-length (WT) Slx5 protein, a small Slx5 domain (207–310) implicated in nuclear localization and dimerization, and a full-length Slx5 deletion construct lacking an arginine-rich region, ∆188–260. Point mutations in Sim1 and 2 are indicated as asterisks. (B) Subcellular localization of GFP-tagged Slx5 truncations (C1–C6) indicated in A. Plasmids expressing GFP-tagged C1–C6 constructs and the Slx5 domain (207–310) were transformed into yeast cells to determine their subcellular localization in comparison to full-length WT Slx5-GFP. Notice nuclear Slx5 foci present in C1 (foci 32 ± 7.3%, n = 352), C2 (foci 42.5 ± 3.72%, n = 271), and C3 (foci 23 ± 10.5%, n = 232). Constructs C4–C6 are distributed throughout the cells, with an additional enrichment of C4 at the bud neck (yellow arrow) of dividing cells (bud neck localization 11.5 ± 1.29%, n = 374). GFP-tagged Slx5(207–310) is enriched in the nucleus (red arrows), suggesting that this domain is important for nuclear localization of Slx5. Reciprocally, an overlapping construct, Slx5(∆188–260)-GFP, is redistributed between the nucleus and the cytosol. The nuclear Slx5-GFP signal averaged 64.5 ± 4.9% (n = 85 nuclei, red arrows, bottom) compared with 56 ± 2.3% (n = 84 nuclei, blue arrows) in the Slx5(∆188-260)-GFP mutant (Kruskal–Wallis test, 109.3; df = 1; p < 0.001). Note that both constructs in the bottom also contain point mutations in Sim1 and Sim2 (indicated by asterisks) to ensure that the localization was unbiased of association with SUMO and sumoylated proteins in the nucleus and the cytosol. Furthermore, the localization of both constructs in the bottom was evaluated in an slx5/slx8 double mutant to prevent association with endogenous Slx5 and Slx8. n, number of log-phase cells imaged and analyzed ± SD.
FIGURE 2:A Slx5 truncation containing four SIMs but lacking the potential nuclear localization domain (207–310) is enriched at the septin ring of G2/M-arrested cells. (A) Cells expressing the YFP-tagged septin protein Cdc3-YFP (YOK1325) were transformed with SLX5(1-207)-CFP (compare construct C4; BOK 507) and then arrested in G2/M before microscopic analysis in live cells. Slx5(1-207)-CFP was present diffusely throughout the cells but was visibly enriched at the bud neck of G2/M-arrested cells (pseudocolored in green), where it colocalized with Cdc3-YFP at the septin ring (pseudocolored in red). Colocalization was observed in ∼80% of cells showing expression of both constructs. (B) The bud neck localization of SLX5(1–207) depends on SIMs and the SUMO ligase Siz1. SLX5(1–207)-GFP (BOK505) and a mutant lacking SIM1 and 2 (1–207(∆sim1/2)) were transformed into yeast cells to determine the requirement for bud neck localization of each construct in G2/M-arrested cells (top left and right). Slx5(1-207)-GFP septin enriched at the bud neck of G2/M-arrested cells was observed in 65 ± 15% of WT cells (n = 162, white arrows). In contrast, septin localization of Slx5(1–207(∆sim1/2)) was greatly reduced or absent (n = 108, yellow arrows). The localization of Slx5(1–207)-GFP was then analyzed in a strain expressing a mutant SUMO protein that fails to form chains (bottom left, smt3(R11,15,19) or strains deleted for the SUMO ligase Siz1, which sumoylates septins (bottom right, siz1∆). Note that bud neck localization was still observed in 27.4 ± 14.9% of smt3(R11,15,19) cells (n = 338) but not in the siz1∆ mutant (yellow arrowhead). n, number of G2/M-arrested cells imaged and analyzed.
FIGURE 3:Slx5 uses distinct domains to interact with Slx8, Slx5, yeast SUMO (Smt3), and Siz1. (A) Graphic depiction of six carboxy-terminal deletions (C1–C6) and six amino-terminal deletions (N1–N6) of Slx5. The length of each truncation construct is indicated by the scale above, with full-length Slx5 being 620 amino acids in length. Also indicated are previously identified SIMs and the RING domain (dark gray) of the full-length (WT) Slx5 protein. (B) Analysis of two-hybrid interaction of WT Slx5 and various Slx5 truncations (C & N). Duplicate spots of yeast cell colony patches indicate two-hybrid interactions of Slx5 with full-length Slx5, Slx8, Smt3, and Siz1 (bottom). Interactions of Slx5, Slx8, Smt3, and Siz1 with individual Slx5 truncations (amino-terminal, N1–N6; carboxy-terminal, C1–C6) correspond to the Slx5 truncations in A (see arrows). Refer to Materials and Methods for details of the two-hybrid analysis. Note that the domain encompassing amino acids 207–310 of Slx5 is required for interaction with full-length Slx5 and that the interaction pattern of Slx5 with SUMO (Smt3) mirrors that with Siz1. (C) Graphic depiction of Slx5 interaction derived from our structure–function analysis in Figures 1 and 2 and this figure. Depicted are Slx5 amino acids 1–620 (increments indicate our constructs), with SIM1–5 and the RING domain, an arginine-rich domain that may be involved in nuclear localization that overlaps the Slx5 interaction domain and is marked with a gray bar.
FIGURE 4:The STUbL subunit Slx5 forms a complex with the SUMO ligase Siz1. (A) Slx5 and Slx8 interact with Siz1 in vitro. Recombinant MBP-Slx5, MBP-Slx8, and T7-tagged Siz1(∆440)-His6 (BOK 500, BOK 501, BOK 758) were produced in bacterial cultures. Then 50 OD units of induced Slx5 and Slx8 cultures were individually combined with 50 OD units of Siz1(∆440). Siz1(∆440), 50 OD units, served as a negative control. Whole-cell extracts from the combined or control cultures (Input) were clarified by centrifugation and passed over a column containing amylose resin. After extensive washing, eluates (elute) corresponding to ∼1 OD unit of input material were analyzed with an anti-T7 antibody (left). Simply Blue staining (Life Technologies) of a gel with duplicate samples (1–3) reveals the bound recombinant Slx5 (∼125 kDa) and Slx8 (∼90 kDa) but not the control Siz1(∆440) protein (∼60 kDa) on the amylose resin (right). (B) Slx5 interacts with Siz1 in vivo. We harvested 20 OD units of cells from strains overexpressing GST-Slx5 only (YOK 2507), GST-Slx5 and Siz1(∆440)-HA (YOK 2509), or Siz1(∆440)-HA only (YOK 2508) and prepared protein extracts by bead-beating. Clarified extracts were passed over individual glutathione agarose columns, and bound proteins were eluted after extensive washing with 10 mM reduced glutathione (lanes 4–6) or sample buffer (lanes 7 and 8). Also shown are input material (0.3% of total OD harvested) for strain YOK 2509 (lane 1) and flowthrough for strains YOK 2509 and YOK 2508 (lanes 2 and 3). “Elute” loaded corresponds to 0.45% of total OD harvested. Presence or absence of Slx5-GST and Siz1(∆440)-HA in each sample is indicated as + or –, respectively. All samples were separated by SDS–PAGE, and individual proteins were detected after Western blotting using anti-GST or anti-HA antibodies as indicated. Note that Siz1(∆440) is only eluted when Slx5-GST is bound to the affinity resin (lanes 5 and 7), indicating an in vivo interaction between the two proteins.
FIGURE 5:Ubiquitylation of Siz1 by Slx5/Slx8 in vitro. In vitro STUbL ubiquitylation reactions, detailed in Materials and Methods, were assembled with the recombinant proteins E1 (Uba1), E2 (Ubc4), and E3 (Slx5 and Slx8), ATP, and substrate (SUB, Siz1(∆440)). As controls, individual components were omitted from the indicated reactions in lanes 1–4 (–ATP, –E2, –E3, –SUB). After incubation, the substrate protein in all reactions was analyzed by immunoblotting with an anti-T7 antibody. Lane 5 contains the complete reaction (ALL) and reveals STUbL-dependent ubiquitylation of Siz1 (Siz1(∆440)-(Ub)n (lane 5). Molecular weights in kilodaltons are indicated on the left. (B) Slx5-dependent ubiquitylation of Siz1∆440 in vivo. Siz1∆440 was expressed in yeast cells (WT or slx5∆), and a ubiquitin-shift assay was used to compare adducts of Siz1∆440 modified either with myc-tagged or untagged ubiquitin G76A (+ or –). Siz1∆440 was detected in whole-cell TCA extracts (WCE) or after immunoprecipitation with anti-V5 agarose (IP). Differentially shifted ubiquitylated adducts of Siz1∆440 are indicated with white and gray arrows (top). Bottom, Western blots of the same samples probed with an anti-myc antibody to reveal shifted bands that correspond to myc-tagged ubiquitin.
FIGURE 6:Slx5 affects the steady-state level and phosphorylation status of Siz1. (A) Altered steady-state level of Siz1 in slx5∆ cells. A heterozygous diploid SLX5/slx5∆ SIZ1/SIZ1-myc/HIS3 strain was sporulated, and the resulting haploid progeny of two tetrads (tetrad 7 [YOK 2279-2282] and tetrad 10 [YOK 2283-2286]) were genotyped (WT and ∆). Proteins were extracted from the indicated haploid strains to determine the steady-state levels of the myc-tagged Siz1 protein in WT and slx5∆ progeny. An anti-myc antibody was used to detect Siz1 on immunoblots of SDS–PAGE–separated proteins. Note the increased steady-state levels and modifications of Siz1 in slx5∆ strains (tetrad 7-4 and tetrad 10-3) in comparison to Siz1 levels in WT strains (tetrad 7-1 and tetrad 10-4). Equal protein loading of all extracts was determined using an anti-Pgk1 antibody. (B) Siz1 is differentially phosphorylated under various growth conditions in WT (YOK 2286) vs. slx5∆ (YOK 2264) cells. Log, untreated, logarithmically growing cells; HU, hydroxyurea treatment to arrest in S phase; NZ, nocodazole treatment to arrest in G2/M. Endogenous, myc-tagged Siz1 protein in WT and slx5∆ cells was detected after immunoblotting of SDS–PAGE–separated proteins using an anti-myc antibody. Single and double asterisks denote differentially phosphorylated forms of Siz1. Equal protein loading of all extracts was determined using an anti-Pgk1 antibody.
FIGURE 7:Slx5 modulates the levels of Siz1 in the nucleus. (A) WT (YOK2738), slx5∆ (YOK2751), msn5∆ (YOK2624), and msn5∆slx5∆ (YOK2735) strains expressing Siz1-GFP as the only copy of this SUMO ligase were imaged during logarithmic growth (log; left) or after nocodazole-induced G2/M arrest (Noc; right). The localization of Siz1-GFP at septins is indicated with yellow arrows, and the localization of nuclei in msn5∆ and msn5∆slx5∆ strains is indicated with white arrowheads. (B) Siz1 is rapidly degraded in an msn5∆ mutant. Isogenic WT (YOK 2397) and msn5∆ (YOK 2514) strains expressing endogenous full-length Siz1-myc were grown overnight in yeast extract/peptone/dextrose (YPD) medium. Cells in logarithmically grown cultures were arrested with nocodazole. G2/M-arrested cells, 10 OD units, were pelleted, washed, and resuspended in fresh YPD medium without nocodazole containing 25 μg/ml cycloheximide. Subsequently, protein extracts of 2.5 OD units of cells were prepared at the indicated time points (0, 10, 30, 60 min) before Western blotting to detect Siz1-myc. Siz1 levels were normalized against the Pgk1 loading control and graphed on the right. (C) A deletion of SLX5 stabilizes Siz1 in an msn5∆ mutant. Isogenic msn5∆ and msn5∆slx5∆ strains expressing Siz1-myc from LEU2/CEN plasmid pRS315 were grown overnight in selective media. Cells in logarithmically grown cultures were arrested with nocodazole and benomyl. G2/M-arrested cells, 22 OD units, were pelleted, washed, and resuspended in fresh YPD medium without nocodazole containing 25 μg/ml cycloheximide. Subsequently, protein extracts of 2 OD units of cells were prepared at the indicated time points (0, 40, 60, 90, 120 min) before Western blotting to detect Siz1-myc and Pgk1 proteins. The first two lanes, msn5∆ (log) and msn5∆slx5∆ (log), are overloaded to show SUMO adducts of Siz1 in these strains. Siz1 levels were normalized against the Pgk1 loading control and graphed on the right. Siz1 protein levels, normalized to the Pgk1 control, were determined using a C-DiGit Western blot scanner (Li-COR, Lincoln, NE) and Image Studio software (Li-COR) and are shown below each time point. (D) Model of a STUbL-dependent nuclear degradation pathway of sumoylated Siz1. At the onset of mitosis nuclear Siz1 becomes autosumoylated (green circles) and phosphorylated (p) via an unknown kinase. Phosphorylated Siz1 may be subject to Msn5-mediated nuclear export to facilitate septin sumoylation in the cytosol. Sumoylated Siz1 that remains in the nucleus as the cell enters mitosis (in our experiments this was accomplished through deletion of MSN5) is subject to STUbL-mediated ubiquitylation (circle labeled Ub) and degradation. Other non–STUbL-dependent pathways for the regulation of Siz1 activity and levels may exist, and the exact structures of the Siz1 conjugates are not known.
Strains and plasmids used in this study.
| Name | Pertinent genotype or background | Plasmid or construction | Reference |
|---|---|---|---|
| MHY500 (YOK819) | Mata his3-Δ200 leu2-3, 112 ura3-52 lys2-801trp1-1gal2 | Li and Hochstrasser (2003) | |
| MHY501 (YOK820) | Matα his3-Δ200 | ||
| BY4741 (YOK1322) | MATa leu2Δ0 met15Δ0 ura3Δ0 | Brachmann | |
| JD52 (YOK2062) | MATa ura3-52 his3-Δ200 leu2-3112 trp1-Δ63 lys2-801 | Dohmen | |
| AH109 (YOK1220) | Cat. No. 630444; Clontech, Mountain View, CA | ||
| YOK1369 | SLX5(1-50)-GFP/LEU2 (BOK514) | This study | |
| YOK1370 | SLX5(1-104)-GFP/LEU2 (BOK515) | This study | |
| YOK1372 | SLX5(1-310)-GFP/LEU2 (BOK517) | This study | |
| YOK1373 | SLX5(1-414)-GFP/LEU2 (BOK518) | This study | |
| YOK1374 | SLX5(1-517)-GFP/LEU2 (BOK519) | This study | |
| YOK1375 | SLX5(1-207)-GFP/LEU2 (BOK507) | This study | |
| YOK1830 | SLX5(208-310)-GFP/LEU2 (BOK637) | This study | |
| YOK1408 | SLX5(1-104)-BD/TRP; SLX5-AD/LEU2 (BOK289) | This study | |
| YOK1411 | SLX5(1-207)-BD/TRP; SLX5-AD/LEU2 (BOK289) | This study | |
| YOK1414 | SLX5(1-310)-BD/TRP; SLX5-AD/LEU2 (BOK289) | This study | |
| YOK1417 | SLX5(1-414)-BD/TRP; SLX5-AD/LEU2 (BOK289) | This study | |
| YOK1420 | SLX5(1-517)-BD/TRP; SLX5-AD/LEU2 (BOK289) | This study | |
| YOK1423 | SLX5(51-620)-BD/TRP; SLX5-AD/LEU2 (BOK289) | This study | |
| YOK1425 | SLX5(105-620)-BD/TRP; SLX5-AD/LEU2 (BOK289) | This study | |
| YOK1428 | SLX5(208-620)-BD/TRP; SLX5-AD/LEU2 (BOK289) | This study | |
| YOK1431 | SLX5(311-620)-BD/TRP; SLX5-AD/LEU2 (BOK289) | This study | |
| YOK1434 | SLX5(415-620)-BD/TRP; SLX5-AD/LEU2 (BOK289) | This study | |
| YOK1437 | SLX5(1-104)-BD/TRP; SLX8-AD/LEU2 (BOK311) | This study | |
| YOK1440 | SLX5(1-207)-BD/TRP; SLX8-AD/LEU2 (BOK311) | This study | |
| YOK1443 | SLX5(1-310)-BD/TRP; SLX8-AD/LEU2 (BOK311) | This study | |
| YOK1446 | SLX5(1-414)-BD/TRP; SLX8-AD/LEU2 (BOK311) | This study | |
| YOK1449 | SLX5(1-517)-BD/TRP; SLX8-AD/LEU2 (BOK311) | This study | |
| YOK1452 | SLX5(51-620)-BD/TRP; SLX8-AD/LEU2 (BOK311) | This study | |
| YOK1455 | SLX5(105-620)-BD/TRP; SLX8-AD/LEU2 (BOK311) | This study | |
| YOK1458 | SLX5(208-620)-BD/TRP; SLX8-AD/LEU2 (BOK311) | This study | |
| YOK1461 | SLX5(311-620)-BD/TRP; SLX8-AD/LEU2 (BOK311) | This study | |
| YOK1464 | SLX5(415-620)-BD/TRP; SLX8-AD/LEU2 (BOK311) | This study | |
| YOK1467 | SLX5-BD/TRP (BOK440); SlX5-AD/LEU2 (BOK289) | This study | |
| YOK1470 | SLX5-BD/TRP (BOK440); SLX8-AD/LEU2 (BOK311) | This study | |
| YOK1518 | SLX5-BD/TRP (BOK440); SMT3-AD/LEU2 (BOK571) | This study | |
| YOK1547 | SLX5(1-50)-BD/TRP SMT3-AD/LEU2 (BOK571) | This study | |
| YOK1550 | SLX5(1-104)-BD/TRP; SMT3-AD/LEU2 (BOK571) | This study | |
| YOK1553 | SLX5(1-207)-BD/TRP; SMT3-AD/LEU2 (BOK571) | This study | |
| YOK1556 | SLX5(1-310)-BD/TRP; SMT3-AD/LEU2 (BOK571) | This study | |
| YOK1559 | SLX5(1-414)-BD/TRP; SMT3-AD/LEU2 (BOK571) | This study | |
| YOK1562 | SLX5(1-517)-BD/TRP; SMT3-AD/LEU2 (BOK571) | This study | |
| YOK1565 | SLX5(51-620)-BD/TRP; SMT3-AD/LEU2 (BOK571) | This study | |
| YOK1568 | SLX5(311-620)-BD/TRP; SMT3-AD/LEU2 (BOK571) | This study | |
| YOK1571 | SLX5(208-620)-BD/TRP; SMT3-AD/LEU2 (BOK571) | This study | |
| YOK1574 | SLX5(311-620)-BD/TRP; SMT3-AD/LEU2 (BOK571) | This study | |
| YOK1577 | SLX5(415-620)-BD/TRP; SMT3-AD/LEU2 (BOK571) | This study | |
| YOK1580 | SLX5(518-620)-BD/TRP; SMT3-AD/LEU2 (BOK571) | This study | |
| YOK1583 | SLX5(518-620)-BD/TRP; SLX8-AD/LEU2 (BOK311) | This study | |
| YOK1586 | SLX5(518-620)-BD/TRP; SLX5-AD/LEU2 (BOK289) | This study | |
| YOK1589 | SLX5(1-50)-BD/TRP SLX8-AD/LEU2 (BOK311) | This study | |
| YOK1592 | SLX5(1-50)-BD/TRP SLX5-AD/LEU2 (BOK289) | This study | |
| YOK1595 | SLX5-BD/TRP (BOK440); SIZ1-AD/LEU2 (BOK582) | This study | |
| YOK1621 | SLX5(1-50)-BD/TRP SIZ1-AD/LEU2 (BOK582) | This study | |
| YOK1625 | SLX5(1-104)-BD/TRP; SIZ1-AD/LEU2 (BOK582) | This study | |
| YOK1627 | SLX5(1-207)-BD/TRP; SIZ1-AD/LEU2 (BOK582) | This study | |
| YOK1630 | AH109 | SLX5(1-310)-BD/TRP; SIZ1-AD/LEU2 (BOK582) | This study |
| YOK1633 | SLX5(1-414)-BD/TRP; SIZ1-AD/LEU2 (BOK582) | This study | |
| YOK1636 | SLX5(1-517)-BD/TRP; SIZ1-AD/LEU2 (BOK582) | This study | |
| YOK1639 | SLX5(51-620)-BD/TRP; SIZ1-AD/LEU2 (BOK582) | This study | |
| YOK1642 | SLX5(311-620)-BD/TRP; SIZ1-AD/LEU2 (BOK582) | This study | |
| YOK1645 | SLX5(208-620)-BD/TRP; SIZ1-AD/LEU2 (BOK582) | This study | |
| YOK1648 | SLX5(311-620)-BD/TRP; SIZ1-AD/LEU2 (BOK582) | This study | |
| YOK1651 | SLX5(415-620)-BD/TRP; SIZ1-AD/LEU2 (BOK582) | This study | |
| YOK1654 | SLX5(518-620)-BD/TRP; SIZ1-AD/LEU2 (BOK582) | This study | |
| YOK1796 | SLX5(SIMAB)-BD/TRP; SLX8-AD/LEU2 (BOK311) | This study | |
| YOK1797 | SLX5(SIMAB)-BD/TRP; SLX8-AD/LEU2 (BOK311) | This study | |
| YOK1798 | SLX5(SIMAB)-BD/TRP; SLX8-AD/LEU2 (BOK311) | This study | |
| YOK1799 | SLX5(SIMAB)-BD/TRP (BOK627); SMT3-AD/LEU2 (BOK571) | This study | |
| YOK1800 | SLX5(SIMAB)-BD/TRP(BOK627); SMT3-AD/LEU2 (BOK571) | This study | |
| YOK1801 | SLX5(SIMAB)-BD/TRP(BOK627); SMT3-AD/LEU2 (BOK571) | This study | |
| YOK2396 | YOK 2373 transformed with | This study | |
| YOK2397 | YOK 2062 transformed with | This study | |
| YOK2514 | YOK 2397 transformed with | This study | |
| YOK2513 | YOK 2396 transformed with | This study | |
| YOK3712 (MHY821) |
| ||
| YOK2264 | slx5Δ SIZ1-13xmyc/HIS5 | MHY821 transformed with | This study |
| YOK2286 | MHY501 transformed with | This study | |
| YOK2373 | YOK2062 with integrated | This study | |
| YOK2505 | YOK2062 with integrated | This study | |
| YOK2681 | YOK2062 with integrated slx5::KANMX4 and | This study | |
| YOK2738 | YOK 2062 transformed with | This study | |
| YOK2751 | YOK 2373 transformed with | This study | |
| YOK2624 | YOK2505 transformed with | This study | |
| YOK2735 | YOK2681 transformed with | This study | |
| YOK2757 | YOK2373 transformed with | This study | |
| YOK2759 | YOK2505 transformed with | This study | |
| YOK2761 | YOK2681 transformed with | This study | |
| YOK2501 | MHY3765: |
| |
| YOK2507 | YOK2501 + | BOK629 (GAL1/10-GST-Slx5) (Open Biosystems Yeast GST Collection) transformed into YOK2501 | This study |
| YOK2508 | YOK2501 + | BOK795 transformed into 2501 | This study |
| YOK2509 | YOK250 + | BOK629 and BOK795 transformed into YOK2501 | This study |
| YOK2379 | pYES2.1-GAL- Siz1Δ440-V5/His6-TOPO; CUP1-UbiG76A-myc in JD52 | BOK794 and BOK309 transformed into YOK2062 | |
| YOK2381 | BOK794 and BOK309 transformed into YOK2373 |